Cargando…
Medical cannabis use in the United States: a retrospective database study
INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a pau...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819290/ https://www.ncbi.nlm.nih.gov/pubmed/33526110 http://dx.doi.org/10.1186/s42238-020-00038-w |
_version_ | 1783638983706673152 |
---|---|
author | Mahabir, V. Kishan Merchant, Jamil J. Smith, Christopher Garibaldi, Alisha |
author_facet | Mahabir, V. Kishan Merchant, Jamil J. Smith, Christopher Garibaldi, Alisha |
author_sort | Mahabir, V. Kishan |
collection | PubMed |
description | INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs. METHODS: We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression. RESULTS: The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3). CONCLUSION: This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions. |
format | Online Article Text |
id | pubmed-7819290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78192902021-01-25 Medical cannabis use in the United States: a retrospective database study Mahabir, V. Kishan Merchant, Jamil J. Smith, Christopher Garibaldi, Alisha J Cannabis Res Review INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs. METHODS: We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression. RESULTS: The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3). CONCLUSION: This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions. BioMed Central 2020-09-29 /pmc/articles/PMC7819290/ /pubmed/33526110 http://dx.doi.org/10.1186/s42238-020-00038-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Mahabir, V. Kishan Merchant, Jamil J. Smith, Christopher Garibaldi, Alisha Medical cannabis use in the United States: a retrospective database study |
title | Medical cannabis use in the United States: a retrospective database study |
title_full | Medical cannabis use in the United States: a retrospective database study |
title_fullStr | Medical cannabis use in the United States: a retrospective database study |
title_full_unstemmed | Medical cannabis use in the United States: a retrospective database study |
title_short | Medical cannabis use in the United States: a retrospective database study |
title_sort | medical cannabis use in the united states: a retrospective database study |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819290/ https://www.ncbi.nlm.nih.gov/pubmed/33526110 http://dx.doi.org/10.1186/s42238-020-00038-w |
work_keys_str_mv | AT mahabirvkishan medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy AT merchantjamilj medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy AT smithchristopher medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy AT garibaldialisha medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy |